The reimbursement rates for many ASC procedures have benefited and will benefit under the new Medicare payment system. One such procedure seeing a noticeable reimbursement boost is endoscopy with ...
LYR-220, Lyra’s second product candidate, is a long-acting anti-inflammatory therapy in development for CRS patients with and without polyps who have recurrent symptoms despite prior ethmoid sinus ...
This new study, which followed patients up to 6 months after functional endoscopic sinus surgery, evaluated results using objective and subjective measures. “Nasal polyps are associated with ...
“The findings of this analysis reveal the favorable role SINUVA can play in the management of recurrent nasal polyps in patients who have had a previous sinus surgery,” said Pablo Stolovitzky, M.D., ...
WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback